Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Akebia Therapeutics (AKBA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Biotech Stock Roundup: Biogen Inks Deal to Boost Pipeline, Sangamo Soars on Pfizer Deal

Quite a few deals were announced this week including by companies like Biogen (BIIB).

SGMO : 7.25 (-7.05%)
AKBA : 13.43 (-3.03%)
VRTX : 119.92 (+1.11%)
IONS : 46.38 (+0.06%)
REGN : 455.17 (-0.12%)
ALXN : 97.70 (-0.81%)
BIIB : 250.80 (-0.86%)
Vifor Pharma and Akebia Announce Exclusive License Agreement to Provide Vadadustat to Fresenius Medical Care in the U.S. Upon FDA Approval

Vifor Pharma Ltd. / Vifor Pharma and Akebia Announce Exclusive License Agreement to Provide Vadadustat to Fresenius Medical Care in the U.S. Upon FDA Approval . Processed and transmitted by Nasdaq Corporate...

AKBA : 13.43 (-3.03%)
Akebia and Vifor Pharma Announce Exclusive License Agreement to Provide Vadadustat to Fresenius Medical Care in the U.S. Upon FDA Approval

--- Additional Funds Support Vadadustat Global Development Program to Data a^'

AKBA : 13.43 (-3.03%)
Akebia Announces First Quarter 2017 Financial Results

Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible...

AKBA : 13.43 (-3.03%)
Akebia Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible...

AKBA : 13.43 (-3.03%)
Akebia Therapeutics (AKBA) Shows Strength: Stock Up 5.8%

Akebia Therapeutics, Inc. (AKBA) shares rose almost 6% in the last trading session.

AKBA : 13.43 (-3.03%)
GRFS : 21.36 (-0.23%)
American Kidney Fund Receives Funding Support to Expand Popular 'ACT on Anemia' Education Program to Reach Spanish Speakers

The American Kidney Fund (AKF) today announced it has received funding support to expand its popular "ACT on Anemia" program by creating new Spanish-language web content and educational materials, along...

AKBA : 13.43 (-3.03%)
Akebia and Otsuka Expand Relationship with Collaboration to Develop and Commercialise Vadadustat in Europe, China and Other Territories

--- Committed Capital and Potential Milestone Payments from Otsuka of up to $865 Million, including $208 million or more in Upfront Payment and Development Funding, as well as Tiered, Double-Digit Royalties...

AKBA : 13.43 (-3.03%)
Akebia and Otsuka Expand Relationship with Collaboration to Develop and Commercialize Vadadustat in Europe, China and Other Territories

--Committed Capital and Potential Milestone Payments from Otsuka of up to $865 Million, Including $208 million or More in Upfront Payment and Development Funding, as well as Tiered, Double-Digit Royalties...

AKBA : 13.43 (-3.03%)
Akebia Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible...

AKBA : 13.43 (-3.03%)
Akebia to Present at the 16th Annual Needham Healthcare Conference

Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible...

AKBA : 13.43 (-3.03%)
Akebia Announces Publication of Phase 2a Results for Vadadustat in Patients with Anemia Related to Chronic Kidney Disease

Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible...

AKBA : 13.43 (-3.03%)
Akebia Announces Fourth Quarter and Full-Year 2016 Financial Results

Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible...

AKBA : 13.43 (-3.03%)
Akebia to Host Conference Call on March 6th to Discuss Full-Year 2016 Financial Results and Corporate Highlights

Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor...

AKBA : 13.43 (-3.03%)
KalVista Pharmaceuticals (KALV) in Focus: Stock Jumps 6%

KalVista Pharmaceuticals, Inc. (KALV) saw its shares rise 6% in the last trading session.

KALV : 7.25 (+2.55%)
AKBA : 13.43 (-3.03%)
The Zacks Analyst Blog Highlights: Gilead Sciences, Celgene, Fate Therapeutics, Exelixis and Akebia Therapeutics

The Zacks Analyst Blog Highlights: Gilead Sciences, Celgene, Fate Therapeutics, Exelixis and Akebia Therapeutics

CELG : 116.78 (+0.03%)
AKBA : 13.43 (-3.03%)
EXEL : 19.35 (-1.12%)
GILD : 64.50 (-0.09%)
FATE : 3.28 (-4.93%)
Forget Gilead, Buy These 5 Biotech Stocks Instead

With Gilead (GILD) providing a not-so-rosy outlook for 2017 as its HCV franchise continues to face challenges, here's a look at 5 biotech stocks that look better-positioned.

CELG : 116.78 (+0.03%)
AKBA : 13.43 (-3.03%)
MNTA : 14.75 (-1.67%)
EXEL : 19.35 (-1.12%)
GILD : 64.50 (-0.09%)
FATE : 3.28 (-4.93%)
Advanced Accelerator (AAAP) Catches Eye: Stock Jumps 5.4%

Advanced Accelerator Applications S.A. (AAAP) moved big last session, as its shares rose over 5% on the day.

AAAP : 38.90 (-0.79%)
AKBA : 13.43 (-3.03%)
Akebia Licenses Portfolio of Novel HIF Compounds from Johnson & Johnson Innovation

Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients through the biology of hypoxia-inducible factor (HIF), today announced...

JNJ : 126.92 (-0.48%)
AKBA : 13.43 (-3.03%)
Concordia International (CXRX) Looks Good: Stock Jumps 11.4%

Concordia International Corp. (CXRX) shares rose over 11% in the last trading session.

CXRX : 1.29 (unch)
AKBA : 13.43 (-3.03%)

Van Meerten Stock Picks

New Age Beverages - Micro Cap for Momentum Investors
I wanted to find a Micro Cap that was hitting All Time Highs, so I used Barchart to sort today's All Time High list first for Micro Caps, then for the most frequent new highs in the last month.
NBEV -0.27
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

Barchart Morning Call

OVERNIGHT MARKETS AND NEWS Jun E-mini S&Ps ( ESM17 -0.19% ) this morning are down -0.09% as prices consolidate following the rally this week to Thursday's new record high. European stocks are down -0.72% to a 1-week low as German... Read More

Chart of the Day

Cooper Companies (COO) is the Barchart Chart of the Day.  The health care products company has a Trend Spotter buy signal, a Weighted Alpha of 34.54+ and gained 34.95% in the last year.
Read More

Brugler Ag Report

Today's Commentary

Corn futures closed the day 3 1/2 to 5 cents higher, as we head into the holiday weekend with some uncertainty about replanting and crop conditions in general. Markets will be open again on Tuesday. Over the past two weeks, corn futures have increase...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.